Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Clobetasol Propionate

FDA-approved product (cream, topical), marketed as Byqlovi, Clobetasol Propionate, Clobetasol Propionate (Emollient) and 10 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Clobetasol Propionate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Psoriasis
  • Psoriasis vulgaris
  • Skin disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids, very potent (group iv)
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis35.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Clobetasol Propionate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Clobetasol Propionate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Maintenance Effect of Clobex Shampoo on Participants With Moderate to Severe Scalp Psoriasis

    NCT00400725 · start 2006-09-29

    Registered record
    Registry ID
    NCT00400725
    Conditions
    Scalp Psoriasis
    Interventions
    Clobex® Shampoo; Clobex® Vehicle Shampoo; Clobex® Shampoo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-09-29
    Completion
    2007-08-20
    Enrolment
    288

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionScalp Psoriasis
    InterventionClobex® Shampoo; Clobex® Vehicle Shampoo; Clobex® Shampoo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis

    NCT00437216 · start 2006-02

    Registered record
    Registry ID
    NCT00437216
    Conditions
    Psoriasis
    Interventions
    Clobetasol Propionate, 0.05%; Clobetasol propionate, 0.05% Spray
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2006-02
    Completion
    2006-07
    Enrolment
    2,488

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionClobetasol Propionate, 0.05%; Clobetasol propionate, 0.05% Spray
    PhaseNot recorded
    Registry statusCompleted

  • Pivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects

    NCT00864500 · start 2005-11

    Registered record
    Registry ID
    NCT00864500
    Conditions
    Healthy
    Interventions
    Clobetasol Propionate 0.05% lotion, single exposure; Clobex TM 0.05% Lotion, single exposure
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-11
    Completion
    2006-02
    Enrolment
    224

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionClobetasol Propionate 0.05% lotion, single exposure; Clobex TM 0.05% Lotion, single exposure
    PhasePhase 1
    Registry statusCompleted

  • Hydroxychloroquine vs. Clobetasol Rinse to Treat Oral Lichen Planus

    NCT00102557 · start 2005-01

    Registered record
    Registry ID
    NCT00102557
    Conditions
    Lichen Planus, Oral
    Interventions
    Hydroxychloroquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-01
    Completion
    2005-10
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLichen Planus, Oral
    InterventionHydroxychloroquine
    PhasePhase 2
    Registry statusCompleted

  • Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis

    NCT00297011 · start 2004-09

    Registered record
    Registry ID
    NCT00297011
    Conditions
    Herpes Labialis
    Interventions
    valacyclovir+clobetasol gel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-09
    Completion
    2008-01
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHerpes Labialis
    Interventionvalacyclovir+clobetasol gel
    PhasePhase 2
    Registry statusCompleted